Mr. Erik Ritchie reports

RISE NANO OPTICS UPLISTS TO OTCQB VENTURE MARKET AND ACHIEVES DTC ELIGIBILITY, EXPANDING ACCESS TO U.S. INVESTORS

Rise Nano Optics Ltd.'s common shares have been approved to commence trading on the OTCQB Venture Market, operated by OTC Markets Group Inc. The company's common shares are also DTC eligible, enhancing the accessibility and efficiency of trading for U.S. investors.

Rise's common shares trade on the OTCQB Venture Market under the symbol RNOLF while continuing to trade on the Canadian Securities Exchange under the symbol EYE.

The OTCQB Venture Market is recognized by the U.S. Securities and Exchange Commission as an established public market, and is designed for entrepreneurial and growth-stage companies committed to providing high-quality disclosure and transparency. The company's OTCQB uplisting, combined with DTC eligibility, is intended to broaden Rise's visibility and improve trading accessibility among U.S. retail investors, institutional investors, family offices and investment advisers.

DTC eligibility enables electronic clearing and settlement of the company's common shares through the Depository Trust Company, reducing costs and accelerating the clearing and settlement process for U.S. broker dealers and investors.

Erik Ritchie, chief commercial officer of Rise Nano Optics, commented: "Expanding access to the U.S. capital markets is an important next step for Rise as we continue to build out our ECP and optical lab partnerships across North America. OTCQB trading and DTC eligibility make it easier for U.S. investors to participate in Rise's growth as we scale SpectraGuard adoption in the United States."

The OTCQB uplisting represents another step in Rise's broader capital market strategy as the company continues to advance its ECP and optical lab partnerships in the United States, strengthen trading liquidity and increase investor awareness in the U.S. market.

About Rise Nano Optics Ltd.

Rise is a health technology company specializing in advanced nanotechnology lens solutions designed to selectively filter high energy visible light wavelengths. Its patented SpectraGuard technology integrates nanomaterial innovation, ophthalmic research and scalable optical engineering to serve both clinical and consumer eyewear markets globally.

We seek Safe Harbor.